HotHouse Therapeutics
- Company typePrivate
- Founded2025
- HeadquartersNorwich, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
HotHouse Therapeutics firmographics
Firmographics- Name
- HotHouse Therapeutics
- Legal name
- Hot House Therapeutics
- Website
- https://hothousetx.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
HotHouse Therapeutics industry classification
Industry- Product category
- AI-Driven Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where HotHouse Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Norwich
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
HotHouse Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Discovery Partnerships and Licensing: HotHouse Therapeutics generates revenue through partnerships with pharmaceutical and biotech companies, offering access to their AI-driven plant-based drug discovery platform for novel therapeutic development. Revenue derived from collaborative research agreements, milestone payments, and potential licensing of discovered compounds.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
HotHouse Therapeutics product offering
Product offeringCore offering
HotHouse Therapeutics operates a dual-platform drug discovery architecture combining AI with plant-based bioengineering. The BotanAI platform initiates and optimizes compound design, while BotanBio delivers scalable chemistry through novel transient and stable plant expression systems. The company reprograms plant biosynthetic pathways to produce therapeutic compounds—including vaccine adjuvants and new-to-nature molecules—that are inaccessible through traditional chemical synthesis, moving from digital concept to high-purity compounds in days rather than years.
Product overview
HotHouse Therapeutics operates a dual-platform architecture consisting of BotanAI and BotanBio. BotanAI serves as the AI-driven design and optimisation engine that transforms plants into sustainable biofactories for identifying next-generation therapeutics. BotanBio delivers the scalable chemistry production, combining AI-generated designs with two novel plant expression systems (transient for development and stable for production) to translate complex chemistry through to GMP. Together, these platforms enable the company to move from digital concept to high-purity compounds in days rather than years.
Differentiator
Problem solved
Functional benefit
Products and services
- BotanAI AI-driven platform that transforms plants into sustainable biofactories, unlocking vaccine adjuvants and new-to-nature therapeutics by initiating and optimising compound design and delivery. Identifies the next generation of therapeutics through AI-guided plant biosynthesis for pharmaceutical, biotech, and global health partners.
- BotanBio Chemistry delivery platform providing scalable, sustainable solutions from vaccine adjuvants to small molecule therapeutics. Combines AI-generated designs with two novel plant expression systems—transient for development and stable for production—to translate complex chemistry through to GMP for pharmaceutical, biotech, and global health customers.
Quantifiable outcome
- Days vs years to move from digital concept to high-purity compound
- +1 more outcomes
Companies that use HotHouse Therapeutics
Customer profileSegments3 records
Ideal customer profiles3 records
HotHouse Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
HotHouse Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Collaborative Drug Discovery (CDD)coreHotHouse Therapeutics implemented CDD Vault, a cloud-based informatics platform, to enhance R&D operations. The platform centralizes experimental and computational data, accelerates lead design decisions, improves collaboration with partners, and maintains full control of intellectual property. CDD Vault supports HotHouse's AI-driven plant biosynthesis work by managing complex datasets.
- John Innes CentrecoreHotHouse Therapeutics is a UK biotech spin-out from the John Innes Centre, a world-leading research institute in plant science and microbiology. The company leverages research and expertise originating from this academic institution, with Chief Science Officer Professor Anne Osbourn OBE FRS FLS having established the foundational science.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
HotHouse Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Isomorphic Labs: Isomorphic Labs is an Alphabet-backed AI drug discovery company with deep computational chemistry capability and large-pharma partnerships. It competes for the same enterprise partnership mindshare that HotHouse is targeting with its plant-based angle.
- Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI for drug discovery at scale across multiple therapeutic areas. Its AI-native discovery model and partnership-based commercialisation mirror HotHouse's go-to-market, though its scale and capital base dwarf HotHouse.
- Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software used by pharma for drug discovery. While its software-and-services model differs, its pursuit of new-to-nature molecules through computation parallels HotHouse's AI design layer.
- Ginkgo Bioworks: Ginkgo Bioworks operates a broad synthetic biology platform for programming cells across pharma, agriculture and industrial markets. Its end-to-end synbio infrastructure and codebase ambition mirror HotHouse's pathway-engineering architecture at much larger scale.
- Insilico Medicine: Insilico Medicine is a leading AI-driven drug discovery company with its own generative chemistry platform and pipeline. Its broader small-molecule focus contrasts with HotHouse's plant-biosynthesis angle, but the AI-for-molecules overlap makes it a key adjacent peer.
Direct peers
- Antheia: Antheia engineers yeast-based synthetic biology platforms to produce active pharmaceutical ingredients currently sourced from plants. Its end-to-end synbio-to-pharma pipeline and focus on plant-derived APIs overlap with HotHouse's plant expression to GMP ambition.
- Ayana Bio: Ayana Bio applies synthetic biology to plant-derived bioactive ingredients for health and wellness applications, directly comparable to HotHouse's plant biosynthetic pathway engineering approach. Both companies target complex, plant-made molecules inaccessible to traditional chemistry.
- Brightseed: Brightseed uses AI to discover bioactive compounds in plants and has built a profile of plant-derived small molecules for health applications. The combination of AI + plant bioactives for therapeutic discovery mirrors HotHouse's platform thesis.
Emerging players
- Atomwise: Atomwise uses AI for small-molecule drug discovery and partners with pharma on novel compound identification. Its partnership-led GTM and AI-native discovery approach is comparable to HotHouse's platform model, with overlap in pharma buyer relationships.
- Cradle Bio: Cradle applies generative AI to protein and biologics design, combining ML with wet-lab iteration. Its AI + biology productisation ethos is comparable, though its modality focus is proteins rather than plant small molecules.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
HotHouse Therapeutics social profiles
Digital presenceHotHouse Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
HotHouse Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
HotHouse Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HotHouse Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HotHouse Therapeutics
What does HotHouse Therapeutics do?
HotHouse Therapeutics operates a dual-platform drug discovery architecture combining AI with plant-based bioengineering. The BotanAI platform initiates and optimizes compound design, while BotanBio delivers scalable chemistry through novel transient and stable plant expression systems. The company reprograms plant biosynthetic pathways to produce therapeutic compounds—including vaccine adjuvants and new-to-nature molecules—that are inaccessible through traditional chemical synthesis, moving from digital concept to high-purity compounds in days rather than years.
Is HotHouse Therapeutics a public or private company?
HotHouse Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was HotHouse Therapeutics founded?
HotHouse Therapeutics was founded in 2025. It employs 1 to 10 people.
Where is HotHouse Therapeutics based?
HotHouse Therapeutics is headquartered in Norwich, United Kingdom, in the Europe region.
How does HotHouse Therapeutics make money?
One revenue line is on record: drug Discovery Partnerships and Licensing.
Who are HotHouse Therapeutics's main competitors?
Broad incumbents on record are Isomorphic Labs, Recursion Pharmaceuticals, Schrödinger, Ginkgo Bioworks and Insilico Medicine. Direct peers are Antheia, Ayana Bio and Brightseed. Emerging players are Atomwise and Cradle Bio.
Does HotHouse Therapeutics have an API?
No public API is recorded for HotHouse Therapeutics.
What industry is HotHouse Therapeutics in?
HotHouse Therapeutics's product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.